Kite Pharma founder’s venture capital firm closes new $600M fund
The new fund, announced Thursday by Arie Belldegrun's Vida Ventures, brings the total amount of money raised to approximately $1 billion.
The new fund, announced Thursday by Arie Belldegrun's Vida Ventures, brings the total amount of money raised to approximately $1 billion.
The filing comes one week after the company, founded earlier this year with a $300 million Series A round by two former Kite executives, raised $120 million in a private financing.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Led by two Kite founders, the company launched with $300 million in VC funding in April and plans a registration trial of Servier's UCART19 and clinical development of its own allogeneic CAR-Ts next year.
Assuming all goes well, potential prostate cancer drug candidate could enter clinic by end of next year, Norbert Bischofberger says.